[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367706-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367706-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","disrupting-cell-cycle-machinery-crept-is-an-emerging-target-in-cancer-therapy","Disrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy","","The transcriptional co-factor CREPT has emerged as a critical driver of cell-cycle control and a meaningful contributor to tumorigenesis. Aberrant or elevated CREPT expression enhances multiple dysregulated signaling pathways, including Wnt/β-catenin, STAT3, and NF-κB/TNFR2, correlating with poor overall survival. Preclinical studies show that CREPT knockdown, such as via shRNA, can produce sustained tumor growth regression. Additional evidence supports pleiotropic roles for CREPT in metabolic regulation, tissue repair, and microenvironment remodeling. Although no direct clinical agent inhibits CREPT expression, miRNA-based strategies and other approaches have shown tumor-suppressive effects. This review connects CREPT to cancer hallmarks and proposes CREPT targeting to reverse tumor growth and improve immune checkpoint inhibitor efficacy in CREPT-driven cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/disrupting-cell-cycle-machinery-crept-is-an-emerging-target-in-cancer-therapy/367706/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/disrupting-cell-cycle-machinery-crept-is-an-emerging-target-in-cancer-therapy/367706.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is CREPT and why is it important in cancer therapy?","Question",{"text":63,"@type":64},"CREPT is a transcriptional co-factor that drives cell-cycle progression and contributes to tumorigenesis. Its overexpression is linked to poor overall survival, making it an emerging therapeutic target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which signaling pathways does CREPT affect?",{"text":68,"@type":64},"CREPT dysregulates several pathways, including Wnt/β-catenin, STAT3, and NF-κB/TNFR2. These pathways are frequently altered across cancers and are associated with abnormal cell behavior.",{"name":70,"@type":61,"acceptedAnswer":71},"Is there a direct clinical drug that inhibits CREPT expression?",{"text":72,"@type":64},"No therapeutic agent directly inhibiting CREPT expression is currently available in the clinic. However, miRNAs and other methods have been used to target CREPT and inhibit tumor growth.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367706,1790889179,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nDisrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy  \nUmar Farooq 1, Jun Li 1,* and Zhijie Chang 2, *  \nAcademic Editor: Maria Mudryj  \nReceived: 25 June 2025  \nRevised: 15 July 2025  \nAccepted: 17 July 2025  \nPublished: 19 July 2025  \nCitation: Farooq, U.; Li, J.; Chang, Z. Disrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy. Cancers 2025, 17, 2401 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17142401  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Jinfeng Laboratory, No. 313 Jinyue Road, High-Tech Zone, Chongqing 401329, China; [umarfarooq@jflab.ac.cn](umarfarooq@jflab.ac.cn)  \n2 State Key Laboratory of Membrane Biology, School of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China  \n* [Correspondence: junlibenben@163.com](Correspondence: junlibenben@163.com) (J.L.); [zhijiec@tsinghua.edu.cn](zhijiec@tsinghua.edu.cn) (Z.C.)  \nSimple Summary  \nCancer is a leading cause of death worldwide, and researchers are continuously working to uncover its drivers and new therapeutic targets. In this review, we explain the role of the oncogenic protein CREPT that is overexpressed in the vast majority of cancers, leading to poor overall survival. CREPT ablation has shown sustained tumor regression in vitro and in mouse models. CREPT activation mediates cancer progression by enhancing the cell cycle by promoting chromatin loop formation. Thus, selectively targeting CREPT expression may provide alternative strategies for inhibiting abnormal cell division, metastasis, and tumor growth, and may improve the efficacy of the currently available therapies in combination, and will be key to reversing cancerous growth in patients with CREPT-driven cancers.  \nAbstract  \nThe transcriptional co-factor cell-cycle-related and expression-elevated protein in tumors (CREPT) has emerged as a critical driver of the cell cycle and a significant contributor to tumorigenesis. The aberrant expression or upregulation of CREPT boosts multiple signaling pathways, including Wnt/β-catenin, STAT3 and NF-κB/TNFR2, which are frequently dysregulated in various cancers and are associated with poor overall survival. In preclinical studies, CREPT knockdown via shRNA has demonstrated sustained tumor growth regression. Recent researches have uncovered additional functions of CREPT, including roles in metabolic regulation, tissue repair, and microenvironmental remodeling, further establishing it as a pleiotropic transcriptional regulator. Currently, there is no therapeutic agent that directly inhibits CREPT expression in clinic. However, miRNAs and other methods have been used to target CREPT, which have yielded useful results in inhibiting tumor growth. In this review, we discuss the role of CREPT in the hallmarks of cancer and propose that targeting CREPT will reverse tumor growth and may improve the immune checkpoint inhibitors in combination in CREPT-driven cancers.  \nKeywords: CREPT; cyclin D1; cell cycle; cancer; therapeutic target  \n1. Introduction  \nTumor development is initiated by perturbation of the cell cycle, resulting in aberrant and uncontrolled cell growth, involving the abnormal expression of both oncogenes and tumor suppressor genes [1] . Oncogenes typically promote cell growth, and mutations or epigenetic alterations can become overactive, leading to uncontrolled cell growth and division [2] . In contrast, tumor suppressor genes are typically responsible for preventing  \nuncontrolled cell division. These genes are often inactivated or lose their function in cancer cells [3] . This imbalance between oncogenes and tumor suppressor ","cbCaigh64HCkf2EO","https://ap.wps.com/l/cbCaigh64HCkf2EO","pdf",5386187,21,"English","# Introduction\n# Simple Summary\n# Abstract\n# Keywords\n# CREPT as a Critical Cell-Cycle Driver\n## Signaling Pathways and Prognosis\n## Preclinical Evidence and Therapeutic Strategies\n# Conclusion and Future Directions","[{\"question\":\"What is CREPT and why is it important in cancer therapy?\",\"answer\":\"CREPT is a transcriptional co-factor that drives cell-cycle progression and contributes to tumorigenesis. Its overexpression is linked to poor overall survival, making it an emerging therapeutic target.\"},{\"question\":\"Which signaling pathways does CREPT affect?\",\"answer\":\"CREPT dysregulates several pathways, including Wnt/β-catenin, STAT3, and NF-κB/TNFR2. These pathways are frequently altered across cancers and are associated with abnormal cell behavior.\"},{\"question\":\"Is there a direct clinical drug that inhibits CREPT expression?\",\"answer\":\"No therapeutic agent directly inhibiting CREPT expression is currently available in the clinic. However, miRNAs and other methods have been used to target CREPT and inhibit tumor growth.\"}]","Disrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy | PDF",1790172155,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/184234d5115f6bcd0ff63f3170cbf23c.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d94808223111cdf92a950c38690b2c1d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95553a6dfc05e756dd032363f695c22a.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e4e432ba7941d803f4cb26b2f0c120f.webp",980,1385]